What happened
Tianxin Pharmaceutical announced on September 3 that it hosted an online research meeting with all investors participating in its 2026 semi-annual earnings briefing.
Company representatives including Director and General Manager Yu Xiaobing, Independent Director Liu Zhen, CFO Luo Xuelin, and Board Secretary Dong Yi answered questions from investors.
In response to a query, management disclosed that the Ningxia production base has an ABL capacity of 13,000 tons per year and a sodium methoxide capacity of 33,000 tons per year (on a dry basis).
Why it matters
This meeting offers investors direct insight into the company's production capacity at a key manufacturing site, which is critical for assessing supply capability and future revenue potential.
The specific capacity figures disclosed for ABL and sodium methoxide help the market evaluate Tianxin's operational scale in these chemical product lines.
Key facts
The event was held on September 3 for the 2026 semi-annual results briefing.
Attendees included the general manager, an independent director, the CFO, and the board secretary.
ABL capacity at the Ningxia base is 13,000 tons/year; sodium methoxide capacity is 33,000 tons/year (dry basis).
What to watch next
Investors may look for further updates on how the Ningxia base's capacity is utilized and whether expansions or operational changes are planned.
Future earnings calls or disclosures may provide additional details on production ramp-up and demand trends for ABL and sodium methoxide.